Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026 | ATNM Stock NewsStockTitan·Oct 23, 2026 at 04:00 AMATNM-7.89%
Actinium Pharmaceuticals (ATNM.US) surged nearly 17% during regular trading to $1.61Market Movers·Oct 22, 2026 at 06:09 PMATNM-7.89%
Actinium Advances ATNM-400 to Higher Dose in Phase 1 Prostate Cancer TrialPUBT·Oct 20, 2026 at 12:10 PMATNM-7.89%
Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Modelsprnewswire·Oct 20, 2026 at 11:33 AMATNM-7.89%
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga_article·Oct 19, 2026 at 05:05 PMADVB-13.88%ATNM-7.89%
Actinium Pharmaceuticals Publishes Presentation on ATNM-400 Antitumor Activity in Ovarian Cancer ModelsPUBT·Oct 19, 2026 at 03:19 PMATNM-7.89%
Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026 | ATNM Stock NewsStockTitan·Oct 19, 2026 at 03:30 AMATNM-7.89%
